Physician profile
Sally Horne
NPI 1215040381
$3,058.27
in general payments reported to CMS, 2019-2025
30 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $233 · 2021: $630 · 2022: $731 · 2023: $503 · 2024: $25.82 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.72 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $762.63 | 2019-2025 | Tysabri |
| Abbvie INC. | $476.24 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $315.73 | 2020-2021 | |
| Emd Serono, INC. | $203.61 | 2019-2022 | |
| Greenwich Biosciences, INC. | $158.36 | 2019 | |
| Allergan, INC. | $136.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.41 | 2019-2022 | |
| Sk Life Science, INC. | $104.15 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.08 | 2022 | |
| Supernus Pharmaceuticals, INC. | $80.92 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $78.32 | 2021-2022 | |
| Genzyme Corporation | $67.19 | 2022 | |
| Ucb, INC. | $65.96 | 2019-2021 | |
| Amgen INC. | $53.35 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $45.99 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $25.82 | 2024 | |
| Banner Life Sciences, LLC | $24.32 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.91 | 2023 | Amvuttra |
| Celgene Corporation | $20.20 | 2022 | |
| Lilly USA, LLC | $20.14 | 2022 | |
| Medtronic USA, INC. | $19.99 | 2019 | |
| Tg Therapeutics, INC. | $19.54 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.01 | 2019 | |
| Smith+Nephew, INC. | $18.23 | 2019 | |
| Horizon Therapeutics Plc | $15.55 | 2022 | |
| Kyowa Kirin, INC. | $12.64 | 2020 | |
| Genentech USA, INC. | $11.16 | 2020 | |
| Sumitomo Pharma America, INC. | $4.54 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Horne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.